These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

215 related items for PubMed ID: 9384246

  • 1. Relative efficacies of cannabinoid CB1 receptor agonists in the mouse brain.
    Burkey TH, Quock RM, Consroe P, Ehlert FJ, Hosohata Y, Roeske WR, Yamamura HI.
    Eur J Pharmacol; 1997 Oct 08; 336(2-3):295-8. PubMed ID: 9384246
    [Abstract] [Full Text] [Related]

  • 2. Antiemetic and motor-depressive actions of CP55,940: cannabinoid CB1 receptor characterization, distribution, and G-protein activation.
    Darmani NA, Sim-Selley LJ, Martin BR, Janoyan JJ, Crim JL, Parekh B, Breivogel CS.
    Eur J Pharmacol; 2003 Jan 10; 459(1):83-95. PubMed ID: 12505537
    [Abstract] [Full Text] [Related]

  • 3. Anandamide- and delta9-tetrahydrocannabinol-evoked arachidonic acid mobilization and blockade by SR141716A [N-(Piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4 -methyl-1H-pyrazole-3-carboximide hydrochloride].
    Shivachar AC, Martin BR, Ellis EF.
    Biochem Pharmacol; 1996 Mar 08; 51(5):669-76. PubMed ID: 8615904
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Activation of brain-type cannabinoid receptors interferes with preimplantation mouse embryo development.
    Yang ZM, Paria BC, Dey SK.
    Biol Reprod; 1996 Oct 08; 55(4):756-61. PubMed ID: 8879486
    [Abstract] [Full Text] [Related]

  • 7. Relationships between ligand affinities for the cerebellar cannabinoid receptor CB1 and the induction of GDP/GTP exchange.
    Kearn CS, Greenberg MJ, DiCamelli R, Kurzawa K, Hillard CJ.
    J Neurochem; 1999 Jun 08; 72(6):2379-87. PubMed ID: 10349847
    [Abstract] [Full Text] [Related]

  • 8. Influence of cannabinoids on electrically evoked dopamine release and cyclic AMP generation in the rat striatum.
    Cadogan AK, Alexander SP, Boyd EA, Kendall DA.
    J Neurochem; 1997 Sep 08; 69(3):1131-7. PubMed ID: 9282935
    [Abstract] [Full Text] [Related]

  • 9. The effects of delta9-tetrahydrocannabinol physical dependence on brain cannabinoid receptors.
    Breivogel CS, Scates SM, Beletskaya IO, Lowery OB, Aceto MD, Martin BR.
    Eur J Pharmacol; 2003 Jan 17; 459(2-3):139-50. PubMed ID: 12524139
    [Abstract] [Full Text] [Related]

  • 10. 3-Substituted pyrazole analogs of the cannabinoid type 1 (CB₁) receptor antagonist rimonabant: cannabinoid agonist-like effects in mice via non-CB₁, non-CB₂ mechanism.
    Wiley JL, Selley DE, Wang P, Kottani R, Gadthula S, Mahadeven A.
    J Pharmacol Exp Ther; 2012 Feb 17; 340(2):433-44. PubMed ID: 22085649
    [Abstract] [Full Text] [Related]

  • 11. Sphingosine and its analog, the immunosuppressant 2-amino-2-(2-[4-octylphenyl]ethyl)-1,3-propanediol, interact with the CB1 cannabinoid receptor.
    Paugh SW, Cassidy MP, He H, Milstien S, Sim-Selley LJ, Spiegel S, Selley DE.
    Mol Pharmacol; 2006 Jul 17; 70(1):41-50. PubMed ID: 16571654
    [Abstract] [Full Text] [Related]

  • 12. Inverse agonist properties of N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2, 4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide HCl (SR141716A) and 1-(2-chlorophenyl)-4-cyano-5-(4-methoxyphenyl)-1H-pyrazole-3-carboxyl ic acid phenylamide (CP-272871) for the CB(1) cannabinoid receptor.
    Meschler JP, Kraichely DM, Wilken GH, Howlett AC.
    Biochem Pharmacol; 2000 Nov 01; 60(9):1315-23. PubMed ID: 11008125
    [Abstract] [Full Text] [Related]

  • 13. Endocannabinoid 2-arachidonyl glycerol is a full agonist through human type 2 cannabinoid receptor: antagonism by anandamide.
    Gonsiorek W, Lunn C, Fan X, Narula S, Lundell D, Hipkin RW.
    Mol Pharmacol; 2000 May 01; 57(5):1045-50. PubMed ID: 10779390
    [Abstract] [Full Text] [Related]

  • 14. Interaction of brain cannabinoid receptors with guanine nucleotide binding protein: a radioligand binding study.
    Petitet F, Jeantaud B, Capet M, Doble A.
    Biochem Pharmacol; 1997 Dec 01; 54(11):1267-70. PubMed ID: 9416978
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Evidence for a new G protein-coupled cannabinoid receptor in mouse brain.
    Breivogel CS, Griffin G, Di Marzo V, Martin BR.
    Mol Pharmacol; 2001 Jul 01; 60(1):155-63. PubMed ID: 11408610
    [Abstract] [Full Text] [Related]

  • 18. Assessment of anandamide interaction with the cannabinoid brain receptor: SR 141716A antagonism studies in mice and autoradiographic analysis of receptor binding in rat brain.
    Adams IB, Compton DR, Martin BR.
    J Pharmacol Exp Ther; 1998 Mar 01; 284(3):1209-17. PubMed ID: 9495885
    [Abstract] [Full Text] [Related]

  • 19. Inhibition of long-term potentiation in rat hippocampal slices by anandamide and WIN55212-2: reversal by SR141716 A, a selective antagonist of CB1 cannabinoid receptors.
    Terranova JP, Michaud JC, Le Fur G, Soubrié P.
    Naunyn Schmiedebergs Arch Pharmacol; 1995 Nov 01; 352(5):576-9. PubMed ID: 8751088
    [Abstract] [Full Text] [Related]

  • 20. Cannabinoid receptor agonist-stimulated [35S]guanosine triphosphate gammaS binding in the brain of C57BL/6 and DBA/2 mice.
    Basavarajappa BS, Hungund BL.
    J Neurosci Res; 2001 May 15; 64(4):429-36. PubMed ID: 11340650
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.